List of Nuedexta drug patents

Nuedexta is owned by Avanir Pharms.

Nuedexta contains Dextromethorphan Hydrobromide; Quinidine Sulfate.

Nuedexta has a total of 2 drug patents out of which 0 drug patents have expired.

Nuedexta was authorised for market use on 29 October, 2010.

Nuedexta is available in capsule;oral dosage forms.

Nuedexta can be used as treatment of pseudobulbar affect.

The generics of Nuedexta are possible to be released after 13 August, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227484 AVANIR PHARMS Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Jul, 2023

(5 months from now)

US7659282 AVANIR PHARMS Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Aug, 2026

(3 years from now)

Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient

Market Authorisation Date: 29 October, 2010

Treatment: Treatment of pseudobulbar affect

Dosage: CAPSULE;ORAL

How can I launch a generic of NUEDEXTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in